Nastilox (Clopidogrel)

Clopidogrel irreversibly blocks the platelet P2Y12 ADP receptor. By preventing ADP from activating this receptor, the drug inhibits the downstream signaling that leads to platelet shape change, granule release, and aggregation, thereby reducing the formation of arterial clots.

The specific dose of clopidogrel is determined by the prescribing clinician based on the patient’s clinical condition and risk profile. In many practice settings, a common maintenance dose is 75 mg taken once daily, but the exact regimen should always follow the prescriber’s order.

Safety data for clopidogrel during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Nastilox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both clopidogrel and aspirin inhibit platelet aggregation but target different pathways. Aspirin irreversibly acetylates cyclooxygenase‑1, reducing thromboxane A2 production, whereas clopidogrel blocks the P2Y12 ADP receptor. Clopidogrel often provides more consistent platelet inhibition in patients who are aspirin‑resistant or require dual antiplatelet therapy after stenting.

Nastilox tablets should be stored at ambient temperature below 25 °C, in the original container, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Nastilox is taken orally with a full glass of water. It can be swallowed with or without food, but patients should follow the dosing schedule prescribed by their healthcare provider and avoid crushing or chewing the tablet unless specifically instructed.

The most serious risks include severe or uncontrolled bleeding such as intracranial hemorrhage, gastrointestinal bleeding, and rare events like thrombotic thrombocytopenic purpura (TTP). Patients should seek immediate medical attention if they notice unusual bruising, blood in stool or urine, severe headache, or signs of an allergic reaction.

Nastilox should be avoided in individuals with active pathological bleeding, a known hypersensitivity to clopidogrel or any of its excipients, and in patients with severe liver disease that impairs drug metabolism. It is also contraindicated in those who have experienced a recent major surgery unless a physician advises otherwise.